


## HDAC-IN-32

Cat. No.:	HY-145687
CAS No.:	2766688-17-7
Molecular Formula:	C <sub>20</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub>
Molecular Weight:	353.41
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	HDAC-IN-32 is a potent HDAC inhibitor with IC <sub>50</sub> s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity <sup>[1]</sup> .
<b>In Vitro</b>	HDAC-IN-32 (compound 9k) induces upregulation of Ac-HH3 and Ac-tubulin in tumor cells and induces apoptosis by cleavage of caspase-3. HDAC-IN-32 induces downregulation of SSRP1 and SPT16 and leads to chromatin damage. HDAC-IN-32 possesses better antimigration activities than SAHA and could reduce the expression level of MMP-2, which plays critical roles in tumor migration <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. "Chen C, et al. Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity. J Med Chem. 2022 Feb 24;65(4):3667-3683. "

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA